For: | Wiseman EF, Ang YS. Risk factors for neoplastic progression in Barrett’s esophagus. World J Gastroenterol 2011; 17(32): 3672-3683 [PMID: 21990948 DOI: 10.3748/wjg.v17.i32.3672] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v17/i32/3672.htm |
Number | Citing Articles |
1 |
Pamela L. Beatty, Olivera J. Finn. Preventing cancer by targeting abnormally expressed self‐antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas. Annals of the New York Academy of Sciences 2013; 1284(1): 52 doi: 10.1111/nyas.12108
|
2 |
Pamela L Beatty, Sandra Cascio, Olivera J Finn. Biomarkers in Cancer Screening and Early Detection. 2017; : 37 doi: 10.1002/9781118468869.ch4
|
3 |
K. V. Puchkov, E. V. Khabarova, E. S. Tishchenko. Two-stage treatment of Barrett's esophagus. Khirurgiya. Zhurnal im. N.I. Pirogova 2019; (9): 18 doi: 10.17116/hirurgia201909118
|
4 |
Carmine Finelli, Giovanni Tarantino. Should visceral fat, strictly linked to hepatic steatosis, be depleted to improve survival?. Hepatology International 2013; 7(2): 413 doi: 10.1007/s12072-012-9406-z
|
5 |
James Britton, Lisa Gadeke, Laurence Lovat, Shaheen Hamdy, Chris Hawkey, John McLaughlin, Yeng Ang. Research priority setting in Barrett's oesophagus and gastro-oesophageal reflux disease. The Lancet Gastroenterology & Hepatology 2017; 2(11): 824 doi: 10.1016/S2468-1253(17)30250-9
|
6 |
Jason D. Conway, David J. Ott, Michael Y. Chen. Dysphagia. Medical Radiology 2012; : 539 doi: 10.1007/174_2012_607
|
7 |
Romy E. Verbeek, Lisanne F. Spittuler, Anique Peute, Martijn G.H. van Oijen, Fiebo J. ten Kate, Jacob R. Vermeijden, Ardi Oberndorff, Jantine W.P.M. van Baal, Peter D. Siersema. Familial Clustering of Barrett's Esophagus and Esophageal Adenocarcinoma in a European Cohort. Clinical Gastroenterology and Hepatology 2014; 12(10): 1656 doi: 10.1016/j.cgh.2014.01.028
|
8 |
Judith Offman, Francesca Pesola, Rebecca C. Fitzgerald, Willie Hamilton, Peter Sasieni. Impact of Barrett oesophagus diagnoses and endoscopies on oesophageal cancer survival in the UK: A cohort study. Cancer Medicine 2022; 11(4): 1160 doi: 10.1002/cam4.4484
|
9 |
Ellen Richmond, Asad Umar. Mechanisms of esophageal adenocarcinoma formation and approaches to chemopreventive intervention. Seminars in Oncology 2016; 43(1): 78 doi: 10.1053/j.seminoncol.2015.12.001
|
10 |
Francisco Valdovinos-Andraca, Isaac Bartnicki-Navarrete, Ambrosio R Bernal-Mendez, Rafael Rafael Barreto-Zuñiga, Adriana F Romano-Munive, Armando Gamboa-Domínguez, Javier Elizondo-Rivera, Daniel Briseño-García, Felix I Tellez-Ávila. Clinical and Endoscopic Differences Between Patients With Barrett’s Esophagus With and Without Dysplasia/Adenocarcinoma. Cureus 2023; doi: 10.7759/cureus.46323
|
11 |
Romilda Cardin, Marika Piciocchi, Chiara Tieppo, Gemma Maddalo, Giovanni Zaninotto, Claudia Mescoli, Massimo Rugge, Fabio Farinati. Oxidative DNA Damage in Barrett Mucosa: Correlation with Telomeric Dysfunction and p53 Mutation. Annals of Surgical Oncology 2013; 20(S3): 583 doi: 10.1245/s10434-013-3043-1
|
12 |
Xue-Song Zhang, Nicole Tegtmeyer, Leah Traube, Shawn Jindal, Guillermo Perez-Perez, Heinrich Sticht, Steffen Backert, Martin J. Blaser, Steven R. Blanke. A Specific A/T Polymorphism in Western Tyrosine Phosphorylation B-Motifs Regulates Helicobacter pylori CagA Epithelial Cell Interactions. PLOS Pathogens 2015; 11(2): e1004621 doi: 10.1371/journal.ppat.1004621
|
13 |
Conor Brosnan, Enda Hannan, William Duggan, Tim Harding, Donal Maguire, Anthony T Stafford. Diagnostic Inaccuracies of Barrett’s Oesophagus on Gastroscopy: Are We Performing Unnecessary Surveillance?. Cureus 2020; doi: 10.7759/cureus.9850
|
14 |
I. Mesteri, L. Beller, S. Fischer-See, S. Schoppmann, J. Lenglinger, F. Wrba, M. Riegler, J. Zacherl. Radiofrequency ablation of Barrett’s esophagus and early cancer within the background of the pathophysiology of the disease. European Surgery 2012; 44(6): 366 doi: 10.1007/s10353-012-0183-7
|
15 |
Pamela L. Beatty, Olivera J. Finn. The Tumor Immunoenvironment. 2013; : 643 doi: 10.1007/978-94-007-6217-6_28
|